| 1 |
Zhang C, Fei Y, Wang H, Hu S, Liu C, Hu R, Du Q. CAFs orchestrates tumor immune microenvironment—A new target in cancer therapy? Front Pharmacol 2023;14. [DOI: 10.3389/fphar.2023.1113378] [Reference Citation Analysis]
|
| 2 |
Korchagina AA, Shein SA, Koroleva E, Tumanov AV. Transcriptional control of ILC identity. Front Immunol 2023;14. [DOI: 10.3389/fimmu.2023.1146077] [Reference Citation Analysis]
|
| 3 |
Cianga VA, Rusu C, Pavel-tanasa M, Dascalescu A, Danaila C, Harnau S, Aanei C, Cianga P. Combined flow cytometry natural killer immunophenotyping and KIR/HLA-C genotyping reveal remarkable differences in acute myeloid leukemia patients, but suggest an overall impairment of the natural killer response. Front Med 2023;10. [DOI: 10.3389/fmed.2023.1148748] [Reference Citation Analysis]
|
| 4 |
Fares J, Davis ZB, Rechberger JS, Toll SA, Schwartz JD, Daniels DJ, Miller JS, Khatua S. Advances in NK cell therapy for brain tumors. NPJ Precis Oncol 2023;7:17. [PMID: 36792722 DOI: 10.1038/s41698-023-00356-1] [Reference Citation Analysis]
|
| 5 |
Koustas E, Trifylli EM, Sarantis P, Papadopoulos N, Papanikolopoulos K, Aloizos G, Damaskos C, Garmpis N, Garmpi A, Matthaios D, Karamouzis MV. Exploiting Autophagy-Dependent Neoantigen Presentation in Tumor Microenvironment. Genes (Basel) 2023;14. [PMID: 36833401 DOI: 10.3390/genes14020474] [Reference Citation Analysis]
|
| 6 |
Feigl FF, Stahringer A, Peindl M, Dandekar G, Koehl U, Fricke S, Schmiedel D. Efficient Redirection of NK Cells by Genetic Modification with Chemokine Receptors CCR4 and CCR2B. Int J Mol Sci 2023;24. [PMID: 36834542 DOI: 10.3390/ijms24043129] [Reference Citation Analysis]
|
| 7 |
Martelli AM, Paganelli F, Truocchio S, Palumbo C, Chiarini F, McCubrey JA. Understanding the Roles of the Hedgehog Signaling Pathway during T-Cell Lymphopoiesis and in T-Cell Acute Lymphoblastic Leukemia (T-ALL). Int J Mol Sci 2023;24. [PMID: 36769284 DOI: 10.3390/ijms24032962] [Reference Citation Analysis]
|
| 8 |
Ma R, Li Z, Chiocca EA, Caligiuri MA, Yu J. The emerging field of oncolytic virus-based cancer immunotherapy. Trends Cancer 2023;9:122-39. [PMID: 36402738 DOI: 10.1016/j.trecan.2022.10.003] [Reference Citation Analysis]
|
| 9 |
Han B, He J, Chen Q, Yuan M, Zeng X, Li Y, Zeng Y, He M, Zhou Q, Feng D, Ma D. ELFN1-AS1 Promotes GDF15-Mediated Immune Escape of Colorectal Cancer from NK cells by Facilitating GCN5 and SND1 Association.. [DOI: 10.21203/rs.3.rs-2471874/v1] [Reference Citation Analysis]
|
| 10 |
Vyas M, Requesens M, Nguyen TH, Peigney D, Azin M, Demehri S. Natural killer cells suppress cancer metastasis by eliminating circulating cancer cells. Front Immunol 2022;13:1098445. [PMID: 36733396 DOI: 10.3389/fimmu.2022.1098445] [Reference Citation Analysis]
|
| 11 |
Lin C, Horwitz ME, Rein LAM. Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond. Int J Mol Sci 2022;24. [PMID: 36613644 DOI: 10.3390/ijms24010204] [Reference Citation Analysis]
|
| 12 |
Kumar V, Bauer C, Stewart JH. Chasing Uterine Cancer with NK Cell-Based Immunotherapies. Future Pharmacology 2022;2:642-659. [DOI: 10.3390/futurepharmacol2040039] [Reference Citation Analysis]
|
| 13 |
Zhou Z, Deng J, Pan T, Zhu Z, Zhou X, Lv C, Li H, Peng W, Lin B, Cai C, Wang H, Cai Y, Wei F, Zhou G. Prognostic Significance of Cuproptosis-Related Gene Signatures in Breast Cancer Based on Transcriptomic Data Analysis. Cancers (Basel) 2022;14. [PMID: 36497253 DOI: 10.3390/cancers14235771] [Reference Citation Analysis]
|
| 14 |
Murugan D, Murugesan V, Panchapakesan B, Rangasamy L. Nanoparticle Enhancement of Natural Killer (NK) Cell-Based Immunotherapy. Cancers 2022;14:5438. [DOI: 10.3390/cancers14215438] [Reference Citation Analysis]
|
| 15 |
Pinto S, Pahl J, Schottelius A, Carter PJ, Koch J. Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers. Trends Immunol 2022;43:932-46. [PMID: 36306739 DOI: 10.1016/j.it.2022.09.007] [Reference Citation Analysis]
|
| 16 |
Tian L, Xu B, Chen Y, Li Z, Wang J, Zhang J, Ma R, Cao S, Hu W, Chiocca EA, Kaur B, Caligiuri MA, Yu J. Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity. Nat Cancer 2022;3:1318-35. [PMID: 36357700 DOI: 10.1038/s43018-022-00448-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 17 |
Nguyen HP, Pham DD, Dinh Nguyen D, Nguyen PV, Bui VA, Hoang MT, Nguyen LT. Evaluating the Safety and Quality of Life of Colorectal Cancer Patients Treated by Autologous Immune Enhancement Therapy (AIET) in Vinmec International Hospitals. Int J Mol Sci 2022;23. [PMID: 36232666 DOI: 10.3390/ijms231911362] [Reference Citation Analysis]
|
| 18 |
Ma S, Caligiuri MA, Yu J. Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy. Trends Immunol 2022:S1471-4906(22)00164-8. [PMID: 36058806 DOI: 10.1016/j.it.2022.08.004] [Reference Citation Analysis]
|
